Discover the Scientific Programme
Explore the three summit days and ten scientific programme sessions reflecting on the current status of clinical trials, the knowledge and trends in the treatment of NAFLD and what the future of research and treatment of NAFLD will be.
Session 1: Epidemiology, disease modifiers, and models of care
- Current epidemiology and future trends
- Nutrition, alcohol, and environmental toxins as (co-) factors of NAFLD
- Case finding, screening of risk populations, and clinical algorithms
- Evolving models of care: How will the future look?
- Panel discussion
Session 2: New technologies for better stratification of patients
- Disease phenotyping by metabolomics and lipidomics
- Are polygenic risk scores ready for clinical routine?
- Machine learning approaches relating to NAFLD
- Digital pathology and image analysis
- Panel discussion
Session 3: Non-invasive fibrosis markers : Present and future
- Serum-based biomarkers: Staging and treatment response
- Imaging biomarkers: Staging and treatment response
- Panel discussion: The future of liver biopsy
Session 4: Mechanisms of disease progression and implications for therapeutic targets
- Advances in understanding intrinsic mechanisms in NAFLD: metabolism
- Advances in understanding intrinsic mechanisms in NAFLD: inflammation, fibrosis
- Organ cross-talk as a NAFLD modulator: gut and adipose tissue
- Organ cross-talk as a NAFLD modulator: brain and endocrine signals
- Panel discussion
Session 5: New approaches to lifestyle modification – case-based discussion
- Case presentation
- Short presentations from different disciplines:
- Nutrition & app specialist
- Exercise trainer
- Bariatric surgeon
- Hepatology - Panel discussion
Session 6: Personalized medicine in 2032 – how will it look like?
- Sexual dimorphism: the overlooked obvious?
- Gut microbiota as a target for personalized NAFLD interventions
- Gene silencing by siRNA treatment
- Biomarkers for personalized NAFLD medicine – thinking outside the box
- Panel discussion
Session 7: Overlooked issues in clinical trials
- Cardiovascular safety
- Extrahepatic malignancies
- Alcohol misuse, depression, anxiety
- The patient’s perspective
- Panel discussion
Session 8: How do pharmacological treatments of comorbidities affect NAFLD – case-based discussion
- Case presentation
- Short presentations from different disciplines:
- Obesity
- Dyslipidemia
- Diabetes
- Hypothyreoidism - Panel discussion
Session 9: Why do trials fail? A critical perspective
- Selonsertib
- Cenicriviroc
- Elafibranor
- Panel discussion: Consequences for future trials?
Session 10: Clinical trial landscape in 2022
- Phase 1-2 drug candidates for non-cirrhotic NASH
- Phase 3 non-cirrhotic NASH
- Cirrhotic NASH
- Discussion
